REGENXBIO, Inc.

Regenxbio Inc. is a biotechnology company focused on the development, manufacturing, and commercialization of gene therapy products. Its primary aim is to treat a variety of diseases by utilizing the NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery system. This technology is intended to address significant medical needs across multiple therapeutic areas, including ophthalmology, metabolic disorders, and neurodegenerative diseases. Regenxbio's gene therapy approach has the potential to provide lasting therapeutic effects with a single administration, thereby fundamentally altering treatment paradigms. The company's efforts contribute significantly to advancements in precision medicine and personalized healthcare. Regenxbio Inc. plays a pivotal role in the biotechnology sector, reflecting the growing importance of genomic research and gene therapy development in modern medicine. As it partners with other biopharmaceutical companies, Regenxbio not only enhances its own capabilities but also fosters innovation across the industry, highlighting the transformative potential of genetic therapies.